Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

NCT IDNCT05915013ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 1

Target enrollment

Study length

about 9.3 years

Ages

18–60

Locations

1 site in CT

What this study is about

Researchers are testing if a treatment combining ketamine and perampanel improves depression symptoms. The trial will examine how stimulating AMPAR receptors affects the anti-depressant response to ketamine in adults with treatment resistant depression.

Simplified from trial records by PatientMatch.

What you may be asked to do

1.Take Ketamine
2.Take Perampanel
3.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Oral

How treatment is administered

Treatment Assignment

Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), perampanel

Drug routes

oral (Oral Tablet)

Body systems

Psychiatry / Mental Health

Screen for this study View on ClinicalTrials.gov